Research Explorer

Uw browser ondersteunt geen JavaScript of JavaScript is niet ingeschakeld. Zonder JavaScript kan sommige functionaliteit van deze webapplicatie uitgeschakeld zijn of foutmeldingen veroorzaken. Raadpleeg om JavaScript in te schakelen de handleiding van uw browser of contacteer uw systeembeheerder.

Project

Opwekken, valideren en gebruik van nanobodies gericht tegen de neovasculaire integrines alphaV en Beta3 in kanker therapie

Output en outcomes

Code

365B2307

Looptijd

01-01-2007 → 31-12-2010

Financiering

Middelen door bilaterale samenwerking (privé en stichtingen)

Promotor

Claude Libert

Onderzoeksdisciplines

Medical and health sciences
- Immunology
- Morphological sciences
- Oncology
- Immunology
- Morphological sciences
- Oncology
- Immunology
- Morphological sciences
- Oncology

Trefwoorden

antilichamen therapie kanker

Projectomschrijving

De basis van dit project is de bevinding dat de integrines AlphaV en Beta3 tot expressie komen op neovasculair endotheel in tumoren en in wondweefsel. Het doel is dan ook om antilichamen te maken die tumoren kunnen vernietigen door deze integrines te inhiberen.

English

Dutch

English

Cookie settings

In addition to functional cookies which are necessary for the website to function, Ghent University uses non-functional cookies such as statistical cookies and social media cookies. These non-functional cookies can also be placed by third parties, for example to measure the use of the site or to share content on social media. Certain media are only available if you accept the cookies. You can set and modify your cookie preferences yourself. Find out what cookies we use and why in the Cookie Statement.

Analytics

AnalyticsWe'll collect information about your visit to our site. It helps us understand how the site is used – what's working, what might be broken and what we should improve.

Powered by